Rising Traumatic Brain Injuries Fueling The Growth Of The Market Due To Increasing Road Accidents: Powering Innovation and Expansion in the Global Seizures Market by 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Seizures Market Through 2025?
The market encompassing seizure treatments has experienced significant expansion recently, set to progress from a valuation of $4.1 billion in the year 2024 to reach $4.34 billion in 2025, reflecting a compound annual growth rate of 5.8%. This upward trajectory observed over the historical period stems from several key factors, including the increasing frequency of epilepsy and related seizure conditions, heightened levels of recognition and successful diagnoses being achieved, greater investment in exploring and developing treatments for central nervous system disorders, amplified support from governmental bodies and charitable organizations focused on epilepsy education, and a growing cohort of elderly individuals.

What's the Projected Size of the Global Seizures Market by 2029?
Anticipated robust expansion marks the outlook for the seizures market, projecting it to reach a valuation of $5.45 billion by the year 2029, driven by a consistent compound annual growth rate (CAGR) of 5.9%. This upward trajectory throughout the projection window is fundamentally fueled by several core factors: the swelling numbers of elderly individuals susceptible to central nervous system ailments, heightened financial outlays directed toward investigating and developing new seizure treatments, escalating global spending on medical care, greater necessity for antiepileptic pharmaceuticals, and a corresponding increase in diagnosed seizure conditions. Key shifts expected to characterize this timeframe encompass progress in technology designed for identifying and tracking seizures, developments influencing the regulatory clearance and payer coverage for medications, headway in the genetic understanding underpinning personalized seizure management strategies, the increasing utilization of virtual health technologies for off-site seizure observation, and ongoing improvements in pharmaceutical options for epilepsy.

View the full report here:
https://www.thebusinessresearchcompany.com/report/seizures-global-market-report

Top Growth Drivers in the Seizures Industry: What's Accelerating the Market?
Anticipated expansion in the seizures market is being driven by the growing frequency of traumatic brain injuries (TBI), which involve harm to the brain resulting from a sudden impact like a blow, jolt, or penetration to the head. This rise in TBIs is closely linked to the escalating number of vehicular accidents, where high-velocity crashes and inattentive driving frequently result in more significant head trauma. Seizures often manifest as an initial sign of TBI, facilitating earlier diagnosis and superior management of any underlying cerebral damage by medical professionals. To illustrate this impact, data indicated in an October 2023 publication from the South Dakota Department of Health (SDDOH), a state governmental entity, revealed that South Dakota recorded the ninth highest age-adjusted mortality rate linked to TBI in 2022, standing at 26.4 fatalities per 100,000 individuals. Additionally, projections released in April 2024 by the American Association of Neurological Surgeons, a professional body located in the US, suggest that yearly TBI occurrences in the United States range from 1.7 to 3.8 million cases. Consequently, the escalating incidence of traumatic brain injuries is fueling the expansion of the seizures market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23511&type=smp

What Trends Will Shape the Seizures Market Through 2029 and Beyond?
Leading firms in the seizures marketplace are innovating with novel dosage forms, like buccal film, as a means to boost both how easily patients can access treatment and adhere to their regimens. This buccal film technology involves a delicate, fast-dissolving strip placed on the inside of the cheek (the buccal mucosa), allowing medication to be directly absorbed into the circulatory system. As an illustration, in the final month of 2024, the American pharmaceutical entity Aquestive Therapeutics Inc. secured orphan drug exclusivity from the U.S. FDA for their product Libervant (diazepam) buccal film, specifically targeting children between two and five years experiencing seizure clusters. This groundbreaking preparation provides a simple, non-intrusive substitute for conventional methods of delivering diazepam, promoting quick uptake via the buccal lining for a swifter therapeutic effect. Being the inaugural and sole FDA-approved orally administered diazepam film formulated for this specific young demographic, Libervant is positioned to simplify caregiver duties and elevate patient adherence, while this period of exclusivity solidifies Aquestive's standing in progressing epilepsy treatments relying on oral film delivery.

What Are the Main Segments in the Seizures Market?
The seizuresmarket covered in this report is segmented -

1) By Drug Type: First Generation Anti-Epileptics; Second Generation Anti-Epileptics; Third Generation Anti-Epileptics
2) By Route Of Administration: Oral; Parenteral; Topical
3) By Distribution Channel: Hospitals Pharmacies; Independent Pharmacies; Online Pharmacies
4) By End-User: Hospitals And Clinics; Ambulatory Surgical Centers; Homecare Settings; Other End-Users

Subsegments:
1) By First Generation Anti-Epileptics: Phenytoin; Carbamazepine; Valproate; Phenobarbital; Primidone; Ethosuximide
2) By Second Generation Anti-Epileptics: Lamotrigine; Levetiracetam; Topiramate; Oxcarbazepine; Zonisamide; Gabapentin; Pregabalin
3) By Third Generation Anti-Epileptics: Lacosamide; Perampanel; Brivaracetam; Eslicarbazepine; Cenobamate

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=23511&type=smp

Which Top Companies are Driving Growth in the Seizures Market?
Major companies operating in the seizures market are Johnson & Johnson Service Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., H. Lundbeck A/S, Zydus Lifesciences Limited, SK Biopharmaceuticals Co. Ltd., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Taro Pharmaceutical Industries Ltd., Marinus Pharmaceuticals Inc., Eton Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc.

Which Regions Will Dominate the Seizures Market Through 2029?
North America was the largest region in the seizures market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seizures market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23511

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.